Stocktoria
Autolus Therapeutics plc AUTL
Autolus Therapeutics plc financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.4M | $10.1M | $1.7M | — | — | — | $2.9M | $1.4M | — | $1.7M |
| R&D expense | $117.7M | $138.4M | $130.5M | $117.4M | $110.8M | $134.9M | $105.4M | $36.1M | — | $16.0M |
| SG&A expense | $131.9M | $101.7M | $46.7M | — | — | — | — | — | — | — |
| Operating income | -$270.5M | -$241.4M | -$179.7M | -$143.4M | -$141.1M | -$168.1M | -$146.1M | -$57.5M | — | -$23.4M |
| Interest expense | $36.7M | $9.3M | $45.1M | $8.9M | $1.1M | $0 | $0 | — | — | — |
| Income tax | $2.0M | $1.5M | -$19,000 | $272,000 | $58,000 | -$24.2M | -$15.2M | -$7.3M | — | -$3.7M |
| Net income | -$287.5M | -$220.7M | -$208.4M | -$148.8M | -$142.1M | -$142.1M | -$123.8M | -$44.8M | -$19.7M | -$19.7M |
| EPS (diluted) | $-1.08 | $-0.86 | $-1.20 | $-1.57 | $-1.97 | $-2.76 | $-2.88 | — | — | — |
| Operating cash flow | -$283.6M | -$206.3M | -$145.6M | -$112.3M | -$117.9M | -$117.8M | -$101.5M | -$31.5M | — | -$16.4M |
| Free cash flow | -$302.6M | -$228.3M | -$156.6M | -$123.1M | -$126.7M | -$132.4M | -$119.8M | -$40.7M | — | -$19.2M |
| Cash & equivalents | $104.1M | $227.4M | $239.6M | $382.4M | $310.3M | — | — | — | — | — |
| Inventory | $33.2M | $4.1M | $0 | — | — | — | — | — | — | — |
| Total assets | $589.1M | $782.7M | $375.4M | $490.3M | $405.6M | $294.2M | $303.5M | $273.2M | $142.7M | $148.7M |
| Total liabilities | $410.9M | $355.4M | $263.9M | $191.6M | $92.2M | $84.2M | $48.7M | $17.7M | — | $6.1M |
| Shareholders' equity | $178.1M | $427.3M | $111.5M | $298.7M | $313.3M | $210.0M | $254.8M | $255.5M | $137.5M | $142.6M |
Growth · year-over-year · Revenue CAGR 113.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +644.9% | +496.0% | — | — | — | — | +106.7% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.